Premium
Risk of extrapyramidal reactions with aripiprazole
Author(s) -
Lam Y. W. Francis
Publication year - 2017
Publication title -
the brown university psychopharmacology update
Language(s) - English
Resource type - Journals
eISSN - 1556-7532
pISSN - 1068-5308
DOI - 10.1002/pu.30197
Subject(s) - aripiprazole , partial agonist , antipsychotic , extrapyramidal symptoms , medicine , dopamine receptor d2 , agonist , pharmacology , schizophrenia (object oriented programming) , adverse effect , dopamine , psychology , receptor , psychiatry
Aripiprazole is a third‐generation antipsychotic with a distinct pharmacological profile. It is a partial agonist at the dopamine D 2 receptor, and as such has comparatively fewer D 2 receptor‐related adverse effects, such as extrapyramidal reactions. Despite this unique receptor activity, case reports have provided evidence that aripiprazole use could be associated with an increased risk of extrapyramidal reactions, primarily in antipsychotic‐naïve patients.